FDA/CE-Mark facility to produce our full range of world-class specialty safety syringes

Sharps Technology, Inc. (NASDAQ: “STSS” and “STSSW”), an innovative medical device company offering patented, best-in-class, single use smart safety syringe products, is announced the Company completed its acquisition of Safegard Medical’s syringe manufacturing facility in Hungary.

“The acquisition of our first manufacturing facility is an important milestone in our transformation from an R&D-focused enterprise to revenue-generating commercial operations,” stated Robert Hayes, CEO of Sharps Technology. “With the acquisition now complete, with the addition of further assembly and manufacturing capacity, our team is confident we can deliver world class products to meet the strong and growing demand for smart safety syringes, a market forecasted to reach $14 billion globally by 2026.”

Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) introduced the "Liby™" System, an advanced form of life support better known by the medical industry as extracorporeal membrane oxygenation (ECMO), used to treat patients with life-threatening heart and lung failure. The Liby™ System is intended to target the $531million global ECMO market. The Inspira Technologies Liby™ system currently under development is expected to be submitted to the U.S. Food and Drug Administration (FDA) for approval, during the first half of 2023.

The Liby™ system with an aerospace-grade aluminum structure designed to be lightweight and highly durable, will be equipped with long battery life to make suitable for patient transfer within hospitals and by ambulances.

Siyata Mobile Inc. (Nasdaq: SYTA/SYTAW), a global vendor of Push-to-Talk over Cellular (PoC) devices and cellular signal booster systems, announced Logic Wireless Europe Ltd., a leading distributor of business-critical communication solutions across the United Kingdom, Australia, New Zealand and the Pacific Islands, will introduce the Siyata SD7 rugged PoC device integrated with ChatterPTT. ChatterPTT is Logic Wireless’s mobile application and gateway solution that intelligently enables different types of communication devices to communicate directly with each other.

Odyssey Health, Inc. (OTC Pink: ODYY), a company focused on developing unique, life-enhancing medical products, announced the completion of all three cohorts in their Phase I Single Ascending Dosing (SAD) clinical trial. Odyssey’s trial involves administering PRV-002, the Company’s novel drug to treat concussion, to healthy human subjects. For SAD, the drug was safe and well tolerated. Concussions represent an ‘unmet’ medical need and affect millions worldwide. A single concussion can significantly increase the risk of Alzheimer’s Disease and other neuropsychiatric disorders.